Neurocrine Biosciences NBIX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's total liabilities?
- Neurocrine Biosciences (NBIX) reported total liabilities of $1.5B in Q1 2026.
- How has Neurocrine Biosciences's total liabilities changed year-over-year?
- Neurocrine Biosciences's total liabilities increased by 30.1% year-over-year, from $1.15B to $1.5B.
- What is the long-term trend for Neurocrine Biosciences's total liabilities?
- Over 5 years (2020 to 2025), Neurocrine Biosciences's total liabilities has grown at a 17.8% compound annual growth rate (CAGR), from $608.5M to $1.38B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.